Hemolysis induced by Left Ventricular Assist Device is associated with proximal tubulopathy

Tristan de Nattes1*, Pierre-Yves Litzler2,3, Arnaud Gay2, Catherine Nafeh-Bizet2, Arnaud François4, Dominique Guerrot1,3

1 Nephrology–Kidney Transplant Unit, Rouen University Hospital, Rouen, France, 2 Thoracic and Cardiovascular Surgery Department, Rouen University Hospital, Rouen, France, 3 INSERM U1096, Rouen University Hospital, Rouen, France, 4 Department of Pathology, Rouen University Hospital, Rouen, France

* tristan.de-nattes@chu-rouen.fr

Abstract

Background

Chronic subclinical hemolysis is frequent in patients implanted with Left Ventricular Assist Device (LVAD) and is associated with adverse outcomes. Consequences of LVADs-induced subclinical hemolysis on kidney structure and function is currently unknown.

Methods

Thirty-three patients implanted with a Heartmate II LVAD (Abbott, Inc, Chicago IL) were retrospectively studied. Hemolysis, Acute Kidney Injury (AKI) and the evolution of estimated Glomerular Filtration Rate were analyzed. Proximal Tubulopathy (PT) groups were defined according to proteinuria, normoglycemic glycosuria, and electrolytic disorders. The Receiver Operating Characteristic (ROC) curve was used to analyze threshold of LDH values associated with PT.

Results

Median LDH between PT groups were statistically different, 688 IU/L [642–703] and 356 IU/L [320–494] in the “PT” and “no PT” groups, respectively p = 0.006. To determine PT group, LDH threshold > 600 IU/L was associated with a sensitivity of 85.7% (95% CI, 42.1–99.6) and a specificity of 84.6% (95% CI, 65.1–95.6). The ROC’s Area Under Curve was 0.83 (95% CI, 0.68–0.98). In the “PT” group, patients had 4.2 [2.5–5.0] AKI episodes per year of exposure, versus 1.6 [0.4–3.7] in the “no PT” group, p = 0.03. A higher occurrence of AKI was associated with subsequent development of Chronic Kidney Disease (CKD) (p = 0.02) and death (p = 0.05).

Conclusions

LVADs-induced subclinical hemolysis is associated with proximal tubular functional alterations, which in turn contribute to the occurrence of AKI and subsequent CKD. Owing to renal toxicity of hemolysis, measures to reduce subclinical hemolysis intensity as canula...
position or pump parameters should be systematically considered, as well as specific nephroprotective therapies.

**Introduction**

Heart transplantation remains the gold standard treatment for end stage heart failure, but due to the lack of grafts, the use of Left Ventricular Assist Devices (LVAD) has continuously increased during the last decades. LVADs improve survival compared to any conventional medical treatment [1] with an overall survival of 83% at 12 months and 46% at 5 years and more than 25000 patients have already been implanted [2].

Changes in renal function after LVADs implantation have been reported, but critical analysis of renal function data is frequently limited, leading to contradictory results [3]. Brisco *et al* reported that 22% of patients improved their glomerular filtration rate (GFR) by 49%, but this improvement was described as generally transient [4]. Hasin *et al* found that 68% of patients with a pre-implantation GFR < 60 mL/min/1.73m² showed a significant improvement of GFR 3 and 6 months after surgery [5]. These data suggest that patients with LVADs implanted in a chronic setting first have an improved kidney function due to better hemodynamic parameters but that secondarily, LVADs could lead to an accelerated decline in GFR due to parenchymal lesions [6]. Moreover, LVADs are associated with Acute Kidney Injury (AKI) with an incidence between 7.4% and 9% [7, 8].

Chronic subclinical hemolysis, which is frequently due to pump thrombosis, can be one of the complications of mechanical circulatory assist devices. Monitoring of the LDH value is considered as a pertinent biomarker and has to be regularly monitored [9]. In other circumstances, such as Sickle Cell Disease (SCD) and paroxysmal nocturnal hemoglobinuria, hemolysis has been established as a cause of proximal tubulopathy [10]. It has also been shown by Muslem *et al* that pre-operative proteinuria before LVADs implantation is associated with mortality and hemodialysis at one year [11]. Furthermore, the need of hemodialysis after LVADs implantation is associated with an increased risk of mortality, underlying the impact of renal function in LVADs patients survival [12]. In the present study, we hypothesized that subclinical hemolysis induced by LVADs is a cause of tubular injury and associated with subsequent decrease in kidney function.

**Materials and methods**

**Study population**

All patients with a *Heartmate II* Left Ventricular Assist Device (Abbott, Inc, Chicagon IL) implanted in Rouen University Hospital between June 2006 and November 2017 were screened by retrospective review. The research procedures were in accordance with the French law and approved by the ethics committee of Rouen, France (CERNI Nr E2018-58). In line with this committee, and considering that the data were analyzed anonymously, consent were not obtained.

Clinical and LVADs data were obtained from the patient’s medical record. Biological data concerning hemolysis, proximal tubulopathy (PT) and renal function were collected from the hospital laboratory. Data were collected every week during the first month, every three months during the first year, and then every six months until the end of follow-up. Baseline MDRD eGFR was calculated with the last stable plasma creatinine available before hospitalization for *Heartmate II* implantation.
Urine analyses were considered only when the corresponding blood analyses were performed on the same day. By retrospective review, alternative etiologies for hemolysis were excluded: There were no hereditary disorders (spherocytosis, sickle cell anemia, G6PD deficiency), Coombs’ tests were negative in all cases, and hemolytic anemia could not be explained by drugs’ toxicity, infectious agent or chronic autoimmune disease. Similarly, etiologies for proximal tubulopathy were systematically excluded.

Follow-up was stopped when LVADs were definitely explanted: heart transplantation or death. In our study, no patient presented a reversible cardiomyopathy.

**Hemolysis and proximal tubulopathy**

We defined subclinical hemolysis as recommended by INTERMACS guidelines [13]: serum lactate dehydrogenase (LDH) level greater than two and one-half times the upper limit of the normal range (i.e > 700 IU/L in our laboratory), without clinical symptoms of hemolysis. Average LDH was calculated for each patient, based on blood samples collected every week during the first month, every three months during the first year, and then every six months until the end of follow-up.

To define PT, we considered proteinuria/creatininuria ratio between 0.15 and 1.5 g/g and presence of glycosuria without hyperglycemia as major criteria, and presence of aseptic leukocyturia, renal potassium waste (hypokalemia < 3.5 mmol/L with inadequate kaliuresis) and hypophosphatemia (serum phosphate < 2.7 mg/dL) as minor criteria (Table 1).

Patients with two major criteria on two urine and blood samples, with at least one minor criterion were included in the Proximal Tubulopathy group (PT group). The other patients were considered as no Proximal Tubulopathy group (no PT group). Due to the fact that diabetic patients may have transient normoglycemic glycosuria related to diabetes, analyzes were also performed after exclusion of this major criterion in diabetic patients.

**Acute kidney injury and chronic kidney disease**

We defined AKI as recommended by the KDIGO 2012 guidelines [14]: increase in plasma creatinine > 26.5 μmol/L within 48 hours, or increase in plasma creatinine > 1.5 fold baseline, which is known or presumed to have occurred within the prior 7 days. Then, we calculated a ratio with the number of AKI per year of Heartmate II exposure. Chronic Kidney Disease (CKD) was defined as recommended by the KDIGO 2012 guidelines.

**Statistical analysis**

Quantitative data were presented as median [25th-75th percentile]. The differences between PT groups were compared with Mann-Whitney U and Chi-square tests. A sensitivity/specificity Receiver Operating Characteristic (ROC) curve test was used to determine the best cut-off.

Table 1. Definition of major and minor criteria of Proximal Tubulopathy (PT). Owing to the fact that diabetic patients may have normoglycemic glycosuria, analyzes were also performed after exclusion of this major criterion in diabetic patients.

| Major criteria | proteinuria/creatininuria ratio between 0.15 and 1.5 g/g |
|---------------|-----------------------------------------------------|
| Minor criteria | glycosuria without hyperglycemia                     |
|               | aseptic leukocyturia                                 |
|               | hypokalemia < 3.5 mmol/L with inadequate kaliuresis  |
|               | serum phosphate < 2.7 mg/dL                          |
| Proximal tubulopathy | two major criteria, on at least two urine and blood samples, + at least one minor criterion. |

https://doi.org/10.1371/journal.pone.0242931.t001
value of the LDH value associated with PT. Statistical analyses were conducted using GraphPad Prism version 6.04, GraphPad Software, La Jolla California USA, and confidence level was set at 0.05.

Results

Forty-four patients were implanted, four patients were excluded because their survival was less than 60 days and six patients were excluded from the Proximal Tubulopathy analysis because of insufficient biological data. Clinical characteristics of the remaining 33 patients are summarized in Table 2. At baseline, no patient had other cause of hemolysis or sign of tubulopathy.

In our unit, all patients were treated by anticoagulation therapy with a therapeutic INR range between 2.0 and 2.5. As previously published, we do not use antiplatelet therapy in order to reduce major bleeding events [15, 16].

Renal function after Heartmate II implantation

Before Heartmate II implantation, 14 patients (42.4%) had a CKD with a baseline MDRD eGFR < 90 mL/min/1.73m² and 9 patients (27.7%) had an eGFR < 60 mL/min/1.73m². Two patients (6.0%) had proteinuria at baseline: one patient in each group (proteinuria/creatininuria ratio was 0.6 g/g for both of them).

At baseline, median plasma creatinine was 109 μmol/L [76–145], MDRD eGFR = 63 mL/min/1.73m² [45–89]. At the end of follow-up, plasma creatinine was 102 μmol/L [86–149], with a eGFR of 60 mL/min/1.73m² [43–81]. Twenty-eight patients (84.8%) had an eGFR < 90mL/min/1.73m², 17 patients (51.5%) an eGFR < 60 mL/min/m², and 2 patients (6.1%) an eGFR < 30mL/min/m². No patient underwent chronic hemodialysis.

| Characteristics                              | N = 33 (%) |
|---------------------------------------------|------------|
| Age (year)                                  | 63 [38–70] |
| Female sex, n (%)                           | 6 (18.1)   |
| Body-mass index                             | 24.91 [22.98–30.01] |
| Diabetes, n (%)                             | 7 (21.2)   |
| Hypertension, n (%)                         | 23 (69.7)  |
| Causes of heart failure, n (%)              |            |
| Ischemic                                    | 21 (63.6)  |
| Dilative                                    | 11 (33.3)  |
| Myocarditis                                 | 1 (3.0)    |
| Estimated GFR < 90 mL/min/1.73m², n (%)     | 14 (42.4)  |
| Estimated GFR < 60 mL/min/1.73m², n (%)     | 9 (27.2)   |
| Plasma creatinine at the implantation (µmol/L) | 109 [76–145] |
| eGFR at the implantation (mL/min/1.73m²)    | 63 [45–89] |
| HMII support duration (days)                | 693 [355–1120] |
| Transplanted, n (%)                         | 18 (54.5)  |
| Dead, n (%)                                 | 10 (30.3)  |
| Bridge to transplantation                   | 3 (30.0)   |
| Destination therapy                         | 7 (70.0)   |
| Alive with HMII, n (%)                      | 5 (12.8)   |
| Bridge to transplantation                   | 3 (60.0)   |
| Destination therapy                         | 2 (40.0)   |

https://doi.org/10.1371/journal.pone.0242931.t002
Twenty-six patients (78.8%) had AKI between hospitalization and LVAD implantation, without requiring hemodialysis. Nineteen patients (57.6%) had AKI the first month after Heartmate II implantation. Six patients (18.2%) had AKI between the first month and hospital discharge. Among these patients, 7 underwent acute hemodialysis. There was no difference at baseline between patients who required acute hemodialysis and others. More, the need of acute hemodialysis after LVADs implantation did not influence the presence or absence of PT (S1 Table). The median total number of AKI was 4.0 [1.0–8.0], which corresponded to 2.5 AKI/year of exposure [0.5–4.4].

**Hemolysis and proximal tubulopathy**

Twenty-two patients (56.4%) developed significant proteinuria (mean proteinuria/creatinuria ratio = 0.97 g/g in proteinuric patients). There was no hematuria. Seventeen patients (43.6%) had normoglycemic glycosuria. Seven patients (21.1%) were considered as “Proximal Tubulopathy” and twenty-six (78.8%) as “no Proximal Tubulopathy”. All patients were classified in their PT group before the first year. Kidney function before implantation was not different between tubulopathy groups.

LDH evolution during the first 18 months is presented in Fig 1. There was a significant difference between the two groups: in “PT” group, median LDH was 688 [643–703] and 356 [320–494] in the “no PT” group, p = 0.006 (Fig 2). The statistical significance persisted after exclusion of normoglycemic glycosuria as major criterion of PT in diabetic patients (p = 0.03).

Six patients had a LVAD thrombosis: 4 patients (15.4%) in the “no PT” group and 2 patients (28.6%) in the “PT” group. All patients were classified in their PT group before occurrence of LVAD thrombosis, and all patients except one died after the pump thrombosis. Three other patients required a pump exchange, all classified in the “no PT” group.

**Acquired von Willebrand disease**

In “PT” group, 3 patients (42.3%) had symptomatic acquired von Willebrand syndrome, versus 14 patients (53.8%) in “no PT” group. All patients had received blood transfusions: 21 [12–36] transfusions per patient in the “PT” group and 29 [16–54] transfusions per patient in the “no PT” group during the entire follow-up period, p = 0.5.

![Evolution of LDH value](https://doi.org/10.1371/journal.pone.0242931.g001)
There was no difference of LDH value between patients with versus without symptomatic acquired von Willebrand syndrome secondary to the Heartmate II, or according to other clinical characteristics (Table 3).

Sensitivity and specificity of LDH cut-off value to determine PT group

The area under curve (AUC) of mean LDH value of each patient for the diagnosis of PT was 0.83 (95% CI, 0.68–0.98). A cut-off of 600 IU/L for mean LDH was associated with a 85.7% sensitivity (95% CI, 42.1–99.6) and 84.6% specificity (95% CI, 65.1–95.6). A cut-off of 700 IU/L was associated with a 28.6% sensitivity (95% CI, 3.7–8.0) and a 84.6% specificity (95% IC, 65.1–95.6). A cut-off of 500 IU/L was associated with a 85.7% sensitivity (95% CI, 42.1–99.6) and a 76.9% specificity (95% IC, 56.3–91.0) (Fig 3).

Acute kidney injury

Incidence of AKI episodes per year of exposure was statistically different between “PT” and “no PT” groups, 4.2 [2.5–5.0] and 1.6 [0.4–3.7] AKI episodes per year of exposure, respectively, p = 0.03 (Fig 4). There was no association between number of AKI and baseline eGFR (p = 0.5).

Patients who died had 3.4 [2.6–4.7] AKI/y versus 1.6 [0.5–4.6] AKI/y in patients who had been subsequently transplanted (p = 0.05).

Chronic kidney disease

Based on the last stable plasma creatinine available, groups defined by the end-of-follow-up MDRD eGFR regardless of PT statue differed significantly in terms of number of AKI per year of exposure. The group with an eGFR between 90 and 60 mL/min/1.73m² had a median of 0.5 [1.3–2.4] AKI/y versus 3.3 [1.5–4.7] AKI/y in the group with an eGFR between 60 and 30 mL/min/1.73m² and 5.4 [2.2–5.8] AKI/y in the group with an eGFR < 30 mL/min/1.73m² (p = 0.001) (Fig 5). A higher occurrence of AKI was therefore associated with subsequent development of CKD.
Table 3. Characteristics of patients according to their Proximal Tubulopathy (PT) group. Values are medians [25th-75th percentile].

| Characteristic                        | PT, n = 7 (21.1%) | No PT, n = 26 (78.8%) | p    |
|---------------------------------------|-------------------|------------------------|------|
| **Baseline characteristics**          |                   |                        |      |
| Age (year)                            | 71 [61–72]        | 62 [57–66]             | 0.07 |
| Diabetes, n (%)                       | 2 (28.6)          | 5 (19.2)               | 0.6  |
| HbA1c (%)                             | 7.8 [7.2–8.4]     | 7.2 [7.0–8.0]          | 0.5  |
| Hypertension, n (%)                   | 5 (71.4)          | 18 (69.2)              | 0.9  |
| Plasma creatinine at the implantation (μmol/L) | 113 [86–137]     | 106 [72–150]          | 0.6  |
| eGFR (mL/min/1.73m²)                  | 57 [48–83]        | 65 [43–96]             | 0.6  |
| **Biological data**                   |                   |                        |      |
| • Hemoglobin (g/dL)                   | 10.9 [9.9–11.7]   | 11.8 [9.5–13.0]        | 0.3  |
| • Total bilirubin (μmol/L)            | 19.0 [13.0–44.0]  | 19.0 [12.8–31.3]       | 0.9  |
| • Albumin (g/dL)                      | 32.0 [30.7–34.0]  | 29.3 [25.5–32.0]       | 0.2  |
| **Blood pressure at the implantation (mmHg)** |                   |                        |      |
| • Systolic                            | 110 [84–115]      | 100 [88–120]           | 0.9  |
| • Diastolic                           | 70 [50–77]        | 70 [55–90]             | 0.5  |
| **Cause of heart failure, n (%)**     |                   |                        |      |
| • Ischemic                            | 4 (57.1)          | 17 (65.4)              | 0.7  |
| • Dilative                            | 3 (42.9)          | 8 (30.8)               | 0.5  |
| • Myocarditis                         | 0                 | 1 (3.8)                |      |
| **INTERMACS classification, n (%)**   |                   |                        | 0.5  |
| • 1                                   | 2 (28.6)          | 5 (19.2)               | 0.5  |
| • 2                                   | 2 (28.6)          | 13 (50.0)              |      |
| • 3                                   | 1 (14.3)          | 5 (19.2)               |      |
| • 4                                   | 2 (28.6)          | 2 (7.7)                |      |
| • 5–7                                 | 0                 | 1 (3.8)                |      |
| **Indication**                        |                   |                        | 0.2  |
| • Destination therapy, n (%)          | 3 (42.9)          | 5 (19.2)               |      |
| • Bridge to transplantation, n (%)    | 4 (57.1)          | 21 (80.8)              |      |
| **Temporary mechanical circulatory support, n (%)** |       |                        | 0.05 |
| • Impella                             | 0                 | 9 (34.6)               |      |
| • ECMO                                | 6 (85.7)          | 13 (50.0)              |      |
| **Resternotomy, n (%)**               |                   |                        | 0.9  |
| • 1                                   | 1 (14.3)          | 4 (15.4)               |      |
| **ICD implantation, n (%)**           |                   |                        | 0.6  |
| • 2                                   | 5 (71.4)          | 16 (61.5)              |      |
| **Follow-up characteristics**         |                   |                        |      |
| HMII support duration (days)           | 511 [332–1091]    | 715 [359–1186]         | 0.9  |
| LDH                                   | 688 [643–703]     | 356 [320–494]          | 0.006|
| Acquired von Willebrand syndrome, n (%)| 3 (42.3)          | 14 (53.8)              | 0.6  |
| Transfusion (n)                       | 21 [12–36]        | 29 [16–54]             | 0.5  |
| Device or driveline infection         | 6 (85.7)          | 20 (76.9)              | 0.6  |
| AKI (n of episode/year)               | 4.3 [2.5–5.0]     | 1.6 [0.4–3.7]          | 0.05 |
| Plasma creatinine at the end of follow-up | 141 [62–152]    | 100 [87–149]           | 0.6  |
| eGFR (mL/min/1.73m²)                  | 46 [42–118]       | 64 [43–80]             | 0.6  |
| **End of follow-up, n (%)**           |                   |                        |      |
| • Transplanted                        | 3 (42.9)          | 15 (57.7)              | 0.7  |
| • Dead                                | 4 (57.1)          | 6 (23.1)               | 0.2  |
| o Destination therapy                 | 3 (75.0)          | 4 (66.7)               |      |
| • Alive with HMII                     | 5 (19.2)          |                        |      |

(Continued)
Discussion

Despite the sample size, this study shows that in patients with Heartmate II device, chronic subclinical hemolysis is frequent and associated with renal outcomes, especially functional hallmarks of proximal tubular injury. Second, considering that LDH value is a commonly used marker of subclinical hemolysis, we propose a LDH threshold of 600 IU/L as an alarm signal for PT. Third, patients with LVADs-related PT present an increased occurrence of AKI. Finally, regardless of the presence of PT, patients who had the more AKI episodes had the worst renal function at the end of the follow up.

Hemolysis and proximal tubulopathy

To date, there is no validated score for the diagnosis of Proximal Tubulopathy. Owing to its physiological function [17], the typical features of PT are low-molecular weight proteinuria [18], glycosuria and phosphaturia. Besides these signs, several indicators of Proximal Tubular...
Dysfunction are validated, mainly in management guidelines of patients infected by HIV who are particularly exposed to drug-induced PT, especially secondary to Tenofovir [19, 20]. Owing to that, red flags in the follow-up of these patients are: hypokalemia, low serum bicarbonate, hypophosphatemia with abnormal fractional excretion of phosphate [21], abnormal fractional excretion of uric acid, glycosuria [22], aminoaciduria and urinary B2 microglobulin [23]. These signs are validated in other diseases as Lowe syndrome [24, 25], drug-toxicities [26], and have been recently used as a cornerstone for the diagnosis of PT in the scope of COVID [27].

Due to its retrospective design, it has been necessary to choose, among those listed, biological elements for which the laboratory techniques did not change across years and which are

![Graph showing AKI and proximal tubulopathy](https://doi.org/10.1371/journal.pone.0242931.g004)

**Fig 4.** AKI and proximal tubulopathy. Number of AKI per year of exposure (median and 25th-75th percentile) to LVAD according to Proximal Tubulopathy (PT), p = 0.03.

![Graph showing number of AKI per year of exposure](https://doi.org/10.1371/journal.pone.0242931.g005)

**Fig 5.** Number of AKI per year of exposure (median and 25th-75th percentile) according to MDRD eGFR at the end of the follow-up, p = 0.001.
widely performed in daily monitoring of LVAD patients. Consequently, we selected proteinuria and glycosuria as major criteria considering that these signs are more specific of tubular alterations. In order to differentiate proteinuria of glomerular versus tubular origin, we considered usual hallmarks of tubular injury, i.e. a low abundance around 1 g/day as compared to glomerular proteinuria which is supposed to be higher than 2 g/day [18]. Moreover, we paid particular attention to hematuria, which is a classical sign of glomerular lesions, and therefore associated with glomerular proteinuria. In our study, no patient had hematuria, which is another argument for a proteinuria from tubular origin.

Owing to the fact that hypokalemia, serum phosphate and aseptic leukocyturia may reflect other issues in patients with LVAD (e.g. diarrhea, malnutrition, treated urinary tract infection...), we made the choice to consider them as minor criteria. At least, specific signs as aminoaciduria or urinary B2 microglobulin were not routinely performed in our unit and were consequently excluded from the analysis. Finally, biological data were collected only in stable periods and patients were classified in the PT group only when two samples several weeks apart revealed the same findings.

Several diseases can induce renal siderosis. In paroxysmal nocturnal hemoglobinuria, there are reports of AKI due to hemosiderosis after acute hemolytic episodes [28], but also chronic tubular toxicity with nephrosiderosis attributed to chronic hemolysis. Moreover, patients with repeated acute hemolytic episodes had interstitial fibrosis which could be an indirect consequence of renal hemolysis toxicity, causing CKD in 20% of patients [29]. In SCD, it has been shown that tubular iron accumulation is correlated with severity of hemolysis and that hemolysis is associated with proteinuria and renal involvement [30]. There are several reports of AKI and nephrosiderosis after acute hemolysis in patients with mechanical heart valves. In 1990, 33 autopsies of patients with mechanical valves were performed. Nephrosiderosis was correlated with the delay since surgery and associated with number of AKI. Mean plasma creatinine was also correlated with severity of siderosis [31].

LVAD implantation can lead to chronic subclinical hemolysis, which is frequently the consequence of pump thrombosis and is statistically associated with higher mortality [32]. LDH is therefore commonly monitored and an increase over 700 IU/L (2.5 fold normal) is predictive of pump thrombosis and cerebrovascular accident [33]. In our study, we also found an association between the severity of hemolysis, estimated through LDH value, and PT which is the first step towards kidney damage: AKI and CKD. We found a threshold of LDH value which should alarm the clinician on an increased risk for kidney disease in patient with LVADs. Indeed, AUC of ROC has a value of 0.83 (95% CI, 0.68–0.98). Using a threshold of 600 IU/L of LDH, sensitivity and specificity were 85.7% (95% CI, 42.1–99.6) and 84.6% (95% CI, 65.1–95.6), respectively. Taken together, this data supports the use of LDH as a simple monitoring tool for the risk of subsequent chronic tubular alterations.

Interestingly, difference in hemolysis intensity was present since the first month after LVAD implantation, and patients were classified into their PT group before the twelfth month post implantation. These observations suggest that tubular injury occurs early and that severe short-term hemolysis can be an important factor in renal outcomes. Identification of individual risk factors explaining renal sensitivity to hemolysis and improved management of hemolysis in early post-operative period could be of major interest.

**LVADs and acute kidney injury**

Several cases of AKI after acute hemolysis have been reported. In our study, we examined occurrence of AKI in stable and chronic subclinical hemolysis. We found an association between PT and the number of AKI, suggesting that chronic proximal tubular functional
alterations can impair kidney adaptability. Although we did not identify a direct association between PT and CKD, which could be explained by the low number of patients, patients with worst renal function at the end of follow-up had more episodes of AKI than patients with normal or mildly impaired renal function. This highlights the need to limit all factors associated with renal aggression, e.g. hemolysis and other nephrotoxic agents. A recent study confirms that AKI is frequent, in approximately 70% of patients, and is associated with mortality one year after LVADs’ implantation [34]. However, our work is the first considering the number of AKI throughout all exposure time and the association with CKD and death, confirming that occurrence of AKI represents an important long-term issue for patients with LVADs support.

**Therapeutic targets: How to limit subclinical hemolysis and renal toxicity?**

In association with general nephroprotective recommendations, limiting subclinical hemolysis and its renal toxicity could be a therapeutic approach. Shear stress due to LVADs’ pump leads to blood trauma and activates several pathways: von Willebrand Factor degradation, platelet and coagulation activations. Occurrence of these complications depends in part on the pump’s physical properties, and recommendations have been proposed to avoid them [35, 36]. Development of more hemocompatible pumps such as magnetic centrifugal-flow pump improves subclinical hemolysis, which is associated with maintenance of endothelial function compared to continuous axial-flow devices [37, 38]. It also has been shown that shallower outflow canula angulation is associated with reduced thrombogenicity [39]. Moreover, the pump rotation speed influences hemodynamic flow and shear stress [40] and the choice of an optimal echo-guided rotation speed is of major interest [41].

In addition, avoiding renal toxicity of hemolysis has been studied. Several diseases can cause chronic hemolysis, including SCD, paroxysmal nocturnal hemoglobinuria and mechanical valves. Although renal involvement in these diseases is generally the consequence of several pathological pathways, the role of chronic hemolysis in renal toxicity is predominant, which suggests a potential benefit of specifically targeted therapeutic options.

In a SCD mouse model, a treatment with human haptoglobin leads to an increased expression of Heme Oxygenase-1 and decreased iron deposition in the kidney [42].

Due to the involvement of Heme Oxygenase-1 in several models of AKI and CKD, this may become an interesting therapeutic option in hemolysis-related kidney injury [43, 44].

In the scope of endothelial dysfunction due to free Hb and free heme, Kasztan et al. evaluated efficiency of ambrisentan, a selective endothelin-A receptor antagonist, in a murine model of SCD. Endothelin-A receptor is activated by endothelin-1, leading to inflammation and vasoconstriction. With daily administration of ambrisentan, long-term tubular and glomerular injuries were prevented [45]. The same team has initiated a clinical trial in which renal function of patients with SCD and treated with ambrisentan will be evaluated (NCT02712346). Validations of these strategies could be of major interest in the scope of LVAD.

**Limitations**

Our study has several limitations due to its retrospective design. Diagnosis of PT lacks the reliability of specific investigations of tubular function. Although this score has not been previously validated, it was built with classical hallmarks of proximal tubular dysfunction and we believe it provides reliable information. Since the study population was stratified post-hoc based on the PT score, potential confounding cannot be excluded. In addition, a validation would theoretically have been required to ascertain the ROC analysis performed. Although this study has a monocentric design, the main characteristics of our population, including
intensity of hemolysis, are comparable to those reported in larger studies. Malnutrition is a frequent issue in chronic heart failure, and could be a potential bias in the estimation of GFR based on plasma creatinine. Moreover, renal function was impaired on an acute mode for most of patients at the time of implantation, and similarly, was frequently unstable at the end of follow-up. It should be noted that most studies on LVADs and renal function faced the same methodological issues regarding GFR.

Conclusion

To our knowledge, this is the first study to demonstrate that LVADs-related hemolysis is associated with renal functional impairment. A LDH value > 600 IU/L is a relevant marker of PT in this population. Moreover, PT is associated with the risk of AKI. Since subclinical hemolysis and the mechanisms leading to its renal toxicity are potentially improvable, we believe that these results may have significant implications for patients implanted with LVADs, and deserves investigations in a larger confirmation cohort.

Supporting information

S1 Table. Characteristics of patients according to the need of acute hemodialysis after LVADs implantation. Values are medians [25th–75th percentile]. ECMO: Extracorporeal Membrane Oxygenation. LDH: Lactate Dehydrogenase. AKI: Acute Kidney Injury. (DOCX)

Author Contributions

Conceptualization: Tristan de Nattes, Pierre-Yves Litzler, Catherine Nafeh-Bizet, Arnaud François, Dominique Guerrot.

Data curation: Tristan de Nattes, Arnaud Gay, Arnaud Francois, Dominique Guerrot.

Formal analysis: Tristan de Nattes.

Investigation: Tristan de Nattes, Pierre-Yves Litzler, Arnaud François, Dominique Guerrot.

Methodology: Tristan de Nattes, Pierre-Yves Litzler, Dominique Guerrot.

Supervision: Dominique Guerrot.

Validation: Pierre-Yves Litzler, Dominique Guerrot.

Writing – original draft: Tristan de Nattes, Pierre-Yves Litzler, Dominique Guerrot.

Writing – review & editing: Tristan de Nattes, Pierre-Yves Litzler, Arnaud Gay, Catherine Nafeh-Bizet, Arnaud François, Dominique Guerrot.

References

1. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001; 345: 1435–1443. https://doi.org/10.1056/NEJMoa012175 PMID: 11794191

2. Kormos RL, Cowger J, Pagani FD, Teuteberg JJ, Goldstein DJ, Jacobs JP, et al. The Society of Thoracic Surgeons Intermacs database annual report: Evolving indications, outcomes, and scientific partnerships. J Heart Lung Transplant. 2019; 38: 114–126. https://doi.org/10.1016/j.healun.2018.11.013 PMID: 30891593

3. Mao H, Katz N, Kim JC, Day S, Ronco C. Implantable Left Ventricular Assist Devices and the Kidney. Blood Purif. 2014; 37: 57–66. https://doi.org/10.1159/000357970 PMID: 24525434
Brisco MA, Kimmel SE, Coca SG, Putt ME, Jessup M, Tang WWH, et al. Prevalence and Prognostic Importance of Changes in Renal Function After Mechanical Circulatory Support. Circ Heart Fail. 2014; 7: 68–75. https://doi.org/10.1161/CIRCHEARTFAILURE.113.00507 PMID: 24214901

Hasin T, Topilsky Y, Schirger JA, Li Z, Zhao Y, Boilson BA, et al. Changes in renal function after implantation of continuous-flow left ventricular assist devices. J Am Coll Cardiol. 2012; 59: 26–36. https://doi.org/10.1016/j.jacc.2011.09.038 PMID: 22192665

Slaughter MS, Pagani FD, Rogers JG, Miller LW, Sun B, Russell SD, et al. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2010; 29: S1–39. https://doi.org/10.1016/j.healun.2010.01.011 PMID: 20181499

John R, Naka Y, Smedira NG, Starling R, Jorde U, Eckman P, et al. Continuous Flow Left Ventricular Assist Device Outcomes in Commercial Use Compared With the Prior Clinical Trial. Ann Thorac Surg. 2011; 92: 1406–1413. https://doi.org/10.1016/j.thoracsur.2011.05.080 PMID: 21958798

Ross DW, Stevens GR, Wanchoo R, Majure DT, Jauhar S, Fernandez HA, et al. Left Ventricular Assist Devices and the Kidney. Clin J Am Soc Nephrol CJASN. 2018; 13: 348–355. https://doi.org/10.2215/CJN.04670417 PMID: 29070522

Cowger JA, Romano MA, Shah P, Shah N, Mehta V, Haft JW, et al. Hemolysis: a harbinger of adverse outcome after left ventricular assist device implant. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2014; 33: 35–43. https://doi.org/10.1016/j.healun.2013.08.021 PMID: 24418732

Nath KA, Hebbel RP. Sickle cell disease: renal manifestations and mechanisms. Nat Rev Nephrol. 2012; 8: 562–571. https://doi.org/10.1038/nrneph.2012.132 PMID: 22726964

Muslem R, Caliskan K, Akin S, Sharma K, Gilotra NA, Brugts JJ, et al. Pre-operative proteinuria in left ventricular assist devices and clinical outcome. J Heart Lung Transplant. 2018; 37: 124–130. https://doi.org/10.1016/j.healun.2017.07.011 PMID: 28781011

Asleh R, Schettle S, Brasouisil A, Killian JM, Stulak JM, Pereira NL, et al. Predictors and Outcomes of Renal Replacement Therapy After Left Ventricular Assist Device Implantation. Mayo Clin Proc. 2019; 94: 1003–1014. https://doi.org/10.1016/j.mayocp.2018.09.021 PMID: 31171114

Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, et al. Fifth INTERMACS Annual Report: Risk Factor Analysis from More Than 6,000 Mechanical Circulatory Support Patients. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2013; 32: 141–156. https://doi.org/10.1016/j.healun.2012.12.004 PMID: 23352390

Palevsky PM, Liu KD, Brophy PD, Chawla LS, Parikh CR, Thakar CV, et al. KDIGO US Commentary on the 2012 KDIGO Clinical Practice Guideline for Acute Kidney Injury. Am J Kidney Dis. 2013; 61: 649–672. https://doi.org/10.1053/j.ajkd.2013.02.349 PMID: 23499048

Slaughter MS, Pagani FD, Rogers JG, Miller LW, Sun B, Russell SD, et al. Clinical Management of Continuous-Flow Left Ventricular Assist Devices. Mayo Clin Proc. 2019; 94: 1003–1014. https://doi.org/10.1016/j.mayocp.2018.09.021 PMID: 31171114

Cowger JA, Romano MA, Shah P, Shah N, Mehta V, Haft JW, et al. Hemolysis: a harbinger of adverse outcome after left ventricular assist device implant. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2014; 33: 35–43. https://doi.org/10.1016/j.healun.2013.08.021 PMID: 24418732

Nath KA, Hebbel RP. Sickle cell disease: renal manifestations and mechanisms. Nat Rev Nephrol. 2012; 8: 562–571. https://doi.org/10.1038/nrneph.2012.132 PMID: 22726964

Muslem R, Caliskan K, Akin S, Sharma K, Gilotra NA, Brugts JJ, et al. Pre-operative proteinuria in left ventricular assist devices and clinical outcome. J Heart Lung Transplant. 2018; 37: 124–130. https://doi.org/10.1016/j.healun.2017.07.011 PMID: 28781011

Asleh R, Schettle S, Brasouisil A, Killian JM, Stulak JM, Pereira NL, et al. Predictors and Outcomes of Renal Replacement Therapy After Left Ventricular Assist Device Implantation. Mayo Clin Proc. 2019; 94: 1003–1014. https://doi.org/10.1016/j.mayocp.2018.09.021 PMID: 31171114

Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, et al. Fifth INTERMACS Annual Report: Risk Factor Analysis from More Than 6,000 Mechanical Circulatory Support Patients. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2013; 32: 141–156. https://doi.org/10.1016/j.healun.2012.12.004 PMID: 23352390

Palevsky PM, Liu KD, Brophy PD, Chawla LS, Parikh CR, Thakar CV, et al. KDIGO US Commentary on the 2012 KDIGO Clinical Practice Guideline for Acute Kidney Injury. Am J Kidney Dis. 2013; 61: 649–672. https://doi.org/10.1053/j.ajkd.2013.02.349 PMID: 23499048

Litzler P-Y, Smail H, Barbay V, Nafeh-Bizet C, Bouchart F, Baste J-M, et al. Is anti-platelet therapy needed in continuous flow left ventricular assist device patients? A single-centre experience. Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg. 2014; 45: 55–59; discussion 59–60. https://doi.org/10.1093/ejcts/ezt228 PMID: 23671203

Netuka I, Litzler P-Y, Berchtold-Herz M, Flecher E, Zimffer D, Damme L, et al. Outcomes in HeartMate II Patients With No Antiplatelet Therapy: 2-Year Results From the European TRACE Study. Ann Thorac Surg. 2017; 103: 1262–1268. https://doi.org/10.1016/j.athoracsur.2016.07.072 PMID: 27743637

Klootwijk ED, Reichold M, Unwin RJ, Kleta R, Warth R, Bockenhauer D. Renal Fanconi syndrome: taking a proximal look at the nephron. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc—Eur Ren Assoc. 2015; 30: 1456–1460. https://doi.org/10.1093/ndt/gfu377 PMID: 25492894

Peterson PA, Evrin PE, Berggaard I. Differentiation of glomerular, tubular, and normal proteinuria: determinations of urinary excretion of beta-2-microglobulin, albumin, and total protein. J Clin Invest. 1969; 48: 1189–1198. https://doi.org/10.1172/JCI106083 PMID: 4978446

Lucas GM, Ross MJ, Stock PG, Shlipak MG, Wyatt CM, Gupta SK, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis Off Publ Infect Dis Soc Am. 2014; 59: e66–138. https://doi.org/10.1093/cid/ciu617 PMID: 25234519

Samarawickrama A, Cai M, Smith ER, Nambiar K, Sabin C, Fisher M, et al. Simultaneous measurement of urinary albumin and total protein may facilitate decision-making in HIV-infected patients with proteinuria. HIV Med. 2012; 13: 526–532. https://doi.org/10.1111/j.1468-1293.2012.01003.x PMID: 22413854

Walton RJ, Bijvoet OL. Nomogram for derivation of renal threshold phosphate concentration. Lancet Lond Engl. 1975; 2: 309–310. https://doi.org/10.1016/s0140-6736(75)92736-1 PMID: 50513

Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D’Agati VD, Markowitz GS. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int. 2010; 78: 1171–1177. https://doi.org/10.1038/ki.2010.318 PMID: 20811330
23. Gatanaga H, Tachikawa N, Kikuchi Y, Teruya K, Genka I, Honda M, et al. Urinary beta2-microglobulin as a sensitive marker for renal injury caused by tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses. 2006; 22: 744–748. https://doi.org/10.1089/aid.2006.22.744 PMID: 16910829

24. Loi M. Lowe syndrome. Orphanet J Rare Dis. 2006; 1: 16. https://doi.org/10.1186/1750-1172-1-16 PMID: 16725554

25. Bockenhauer D, Bokenkamp A, van't Hoff W, Levchenko E, Kist-van Holthe JE, Tasic V, et al. Renal phenotype in Lowe Syndrome: a selective proximal tubular dysfunction. Clin J Am Soc Nephrol CJASN. 2008; 3: 1430–1436. https://doi.org/10.2215/CJN.00520108 PMID: 18480301

26. Hall AM, Bass P, Unwin RJ. Drug-induced renal Fanconi syndrome. QJM Mon J Assoc Physicians. 2014; 107: 261–269. https://doi.org/10.1093/qjmed/hct258 PMID: 24368854

27. Kormann R, Jacquot A, Alla A, Corbel A, Koszutski M, Voirin P, et al. Coronavirus disease 2019: acute Fanconi syndrome precedes acute kidney injury. Clin Kidney J. 2020; 13: 362–370. https://doi.org/10.1093/ckj/sfaa109 PMID: 32693237

28. Chow K-M, Lai FM-M, Wang AY-M, Chan Y-L, Tang NL-S, Li PK-T. Reversible Renal Failure in Paroxysmal Nocturnal Hemoglobinuria. Am J Kidney Dis. 2001; 37: e17.1–e17.6. https://doi.org/10.1053/ajkd.2001.121361 PMID: 11157403

29. Kokoris SI, Gavriilaki E, Miari A, Travlou AS, Gavriilaki E, Anagnostopoulou A, et al. Renal involvement in paroxysmal nocturnal hemoglobinuria: an update on clinical features, pathophysiology and treatment. Hematology. 2018; 0: 1–9. https://doi.org/10.1007/s00467-018-144563 PMID: 29486674

30. Gurkan S, Scarponi KJ, Hotchkiss H, Savage B, Drachman R. Lactate dehydrogenase as a predictor of kidney involvement in patients with sickle cell anemia. Pediatr Nephrol. 2010; 25: 2123–2127. https://doi.org/10.1007/s00467-010-1560-8 PMID: 20517617

31. Pardo-Mindán FJ, Diez J, Esparza N, Robledo C. Renal Siderosis in Patients with Heart-Valve Prostheses: Clinical Implications. Nephrol Dial Transplant. 1990; 5: 847–850. https://doi.org/10.1093/ndt/5.10.847 PMID: 2128378

32. Zayat R, Shaibi M, Khattab MA, Ahmad U, Goetzenich A, Stoppe C, et al. Are elevated serum haemolysis markers a harbinger of adverse events in HeartMate II patients? Interact Cardiovasc Thorac Surg. 2018. https://doi.org/10.1093/icvts/ivy027 PMID: 29444250

33. Levin AP, Saeed O, Willey JZ, Levin CJ, Fried JA, Patel SR, et al. Watchful Waiting in Continuous-Flow Left Ventricular Assist Device Patients With Ongoing Hemolysis Is Associated With an Increased Risk for Cerebrovascular Accident or Death. Circ Heart Fail. 2016; 9. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002896 PMID: 27166248

34. Muslem R, Caliskan K, Akin S, Sharma K, Giotora NA, Constantinescu AA, et al. Acute kidney injury and 1-year mortality after left ventricular assist device implantation. J Heart Lung Transplant. 2018; 37: 116–123. https://doi.org/10.1016/j.healun.2017.11.005 PMID: 29174532

35. Maltais S, Kilic A, Nathan S, Keebler M, Emani S, Ransom J, et al. PREVENTion of HeartMate II Pump Thrombosis Through Clinical Management: The PREVENT multi-center study. J Heart Lung Transplant. 2017; 36: 1–12. https://doi.org/10.1016/j.healun.2016.10.001 PMID: 27865732

36. Thamsen B, Blümel B, Schaller J, Paschereit CO, Affeld K, Goubergrits L, et al. Numerical Analysis of Blood Damage Potential of the HeartMate II and HeartWare HVAD Rotary Blood Pumps. Artif Organs. 2015; 39: 651–659. https://doi.org/10.1111/aor.12542 PMID: 26234447

37. Mehra MR, Goldstein DJ, Uriel N, Joseph C, Cleveland J, Yuzefpolskaya M, Salerno C, et al. Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure. N Engl J Med. 2018 [cited 30 May 2019]. https://doi.org/10.1056/NEJMoa1800866 PMID: 29526139

38. Bansal A, Uriel N, Colombo PC, Narsetty K, Long JW, Bhimaraj A, et al. Effects of a fully magnetically levitated centrifugal-flow or axial-flow left ventricular assist device on von Willebrand factor: A prospective multicenter clinical trial. J Heart Lung Transplant. 2019;0. https://doi.org/10.1016/j.healun.2019.05.006 PMID: 31147187

39. Aliseda A, Chivukula VK, McGah P, Prisco AR, Beckman JA, Garcia GJM, et al. LVAD Outflow Graft Angle and Thrombosis Risk. ASAIO J Am Soc Artif Intern Organs. 2017; 63: 847–850. https://doi.org/10.1093/maf/MAT.000000000000443 PMID: 28033200

40. Selgrade BP, Truskey GA. Computational Fluid Dynamics Analysis to Determine Shear Stresses and Rates in a Centrifugal Left Ventricular Assist Device. Artif Organs. 2012; 36: E89–E96. https://doi.org/10.1111/j.1525-1594.2011.01416.x PMID: 22360826

41. Stainback RF, Estep JD, Agler DA, Birks EJ, Bremer M, Hung J, et al. Echocardiography in the Management of Patients with Left Ventricular Assist Devices: Recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr. 2015; 28: 853–909. https://doi.org/10.1016/j.echo.2015.05.008 PMID: 26239899
42. Shi PA, Choi E, Chintagari NR, Nguyen J, Guo X, Yazdanbakhsh K, et al. Sustained treatment of sickle cell mice with haptoglobin increases HO-1 and H-ferritin expression and decreases iron deposition in the kidney without improvement in kidney function. Br J Haematol. 2016; 175: 714–723. https://doi.org/10.1111/bjh.14280 PMID: 27507623

43. Adedoyin O, Boddu R, Trayor A, Lever JM, Bolisetty S, George JF, et al. Heme oxygenase-1 mitigates ferroptosis in renal proximal tubule cells. Am J Physiol Renal Physiol. 2018; 314: F702–F714. https://doi.org/10.1152/ajprenal.00044.2017 PMID: 28515173

44. Bolisetty S, Zanjou A, Agarwal A. Heme Oxygenase 1 as a Therapeutic Target in Acute Kidney Injury. Am J Kidney Dis Off J Natl Kidney Found. 2017; 69: 531–545. https://doi.org/10.1053/j.ajkd.2016.10.037 PMID: 28139396

45. Kasztan M, Fox BM, Speed JS, De Miguel C, Gohar EY, Townes TM, et al. Long-Term Endothelin-A Receptor Antagonism Provides Robust Renal Protection in Humanized Sickle Cell Disease Mice. J Am Soc Nephrol JASN. 2017; 28: 2443–2458. https://doi.org/10.1681/ASN.2016070711 PMID: 28348063